The team at Shaw and Partners have used the recent reporting season as an opportunity to have another look at some of the companies they cover, with two in particular standing out as presenting some possible large upside.
Let’s have a look at the companies they like.
Beamtree Holdings Ltd (ASX: BMT)
Beamtree is a healthcare technology company which, in its own words, “applies deep clinical, coding and data expertise combined with AI to help hospitals and pathology labs improve clinical quality, coding accuracy, and reimbursement outcomes”.
The company said in a recent shareholder update that it had undertaken a strategic review which led to it refining its product mix, reshaping its cost base and strengthening its executive team.
The company added:
Going forward, we are focusing our investment on the products with strongest customer resonance, margin potential and capacity for innovation, namely our market leading Diagnostics product (Rippledown), our Coding solutions (PICQ and PICQ Audit, RISQ) and our Analytics platform. This year we are launching our Autonomous Coding Solutions (ACS) product and our Autonomous Data Entry (ADE) product with selected customers.
Shaw and Partners in its research note on the company said the company’s full year result of $29.2 million in revenue and negative EBITDA of $3.5 million was broadly as expected.
The broker said the business had a solid foundation to grow from, with execution now the key.
They have reduced their price target on the company from 30 cents to 25 cents, however this is still well above the current level of 10 cents.
NobleOak Life Ltd (ASX: NOL)
This small cap life insurance provider delivered a net profit of $14.1 million in FY26, up 98% while its in-force premiums grew 18% to $549.2 million.
The company’s Chief Executive Officer Anthony Brown said it was a good year, with the company achieving strong market share gains.
He added:
We are executing our growth strategy and during the year launched new partnerships and products including a new alliance with nib, one of Australia’s largest private health insurers, which is delivering encouraging early results and is expected to accelerate in FY27. Disciplined underwriting, ongoing investment in technology and AI, and a relentless focus on our customer continue to underpin our performance. As we transition from a Friendly Society to a Life Company, we are well positioned and well capitalised to deliver our next growth phase.
Shaw and Partners said NobleOak beat its guidance for both in-force premiums and underlying net profit.
The broker has a price target of $3 on the shares, compared to $1.23 currently.
The post 2 ASX small caps which could rise 140% to %150 appeared first on The Motley Fool Australia.
Should you invest $1,000 in Beamtree right now?
Before you buy Beamtree shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Beamtree wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 1 August 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- 3 fantastic ASX ETFs for Aussie investors in September
- This ASX 200 stock has fallen 32% from its high. Is it finally cheap?
- Santos versus Woodside shares: Which ASX energy stock outperformed in August?
- Could this ASX tech company really rise 180%?
- Corporate Travel Management swings to profit as earnings jump in FY26
Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Beamtree. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.